In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for
Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results …

Alzheimer's disease (AD) is a multifactorial disease with genetic (70%) and environmental
(30%) causes. Among the genetic factors are genes associated with a family history of the …

Background Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2
(PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD …

Familial Alzheimer's disease (FAD) has been shown to be genetically heterogeneous, with a
very small proportion of early onset pedigrees being associated with mutations in the …

Alzheimer's disease is increasingly recognized to be linked to the function and status of
metal ions, and recently, the amyloid hypothesis has been strongly intertwined with the …

Cerebral amyloid angiopathy (CAA) is an important cerebral small vessel disease
associated with brain haemorrhage and cognitive change. The commonest form, sporadic …

The present invention relates to a first group of novel genes, here identified as “genomic
address messenger” or “GAM” genes, and a second group of novel operon-like genes, here …

Significance: Epidemiological studies indicate that metabolic disorders are associated with
an increased risk for Alzheimer's disease (AD). Metabolic remodeling occurs in the central …

Cerebral amyloid angiopathy is commonly associated with normal aging and Alzheimer's
disease and it is also the principal feature of hereditary cerebral hemorrhage with …

Alzheimer's disease (AD) is the most common cause of dementia in the elderly population.
Dementia is associated with massive accumulation of fibrillary aggregates in various cortical …